A Phase 3 interventional study of Lurasidone in Bipolar I Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 71 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-22.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.
Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 11 in phase 3, and was the 6th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
Martin Lan · Sites in United States
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 377 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 348 across the 17 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 9 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
1 of the studies testing lurasidone in Bipolar Disorder that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing lurasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center,12 week extension study designed to evaluate the longer term safety, tolerability and effectiveness of lurasidone, flexibly dosed, adjunctive to lithium or divalproex for the treatment of subjects with bipolar I disorder, who have either completed the core study D1050296 or experienced a protocol defined recurrence of a mood event in the double-blind phase of the core study D1050296
To evaluate the longer term safety of lurasidone (20, 40, 60 or 80 mg/day) in subjects with bipolar I disorder.
Subjects will be initially treated with open-label lurasidone 40 mg/day (Day 1).
Dose adjustment of study drug (20, 40, 60 or 80 mg /day) should occur at the regularly scheduled visits and in increments/decrements of 1 dose level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 20, 40, 60,80 mg flexible dose
Drug: Lurasidone
Lurasidone 20-80 mg taken orally once daily
Treatment-emergent Adverse Events and Treatment-emergent Adverse Events Leading to Discontinuation and Serious Adverse Events
Number of subjects with treatment emergent AEs, SAEs, and TEAEs leading to discontinuation
Time frame: 12 weeks
Change From Baseline to Week 12 (LOCF) in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR16) Total Score
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
Time frame: baseline, 12 weeks (LOCF)
Change From Baseline to Week 12 (LOCF) in the Positive and Negative Syndrome Scale Positive Subscale (PANSS P) Score
The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time frame: baseline, 12 weeks (LOCF)
Change From Baseline to Week 12 (LOCF) in the YMRS Total Score -Mania as Assessed by Young Mania Rating Scale (YMRS)
Movement disorders as assessed by Young Mania Rating Scale (YMRS) The YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of mania.
Time frame: Baseline, 12 weeks (LOCF)
Change From Baseline to Week 12 (LOCF) in the MADRS Total Score- Depression as Assessed by Montgomery-Asberg Depression Rating Scale (MADRS)
Depression as assessed by Montgomery-Asberg Depression Rating Scale (MADRS) -The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depression.
Time frame: baseline ,Week 12 (LOCF)
Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Overall Score- Severity of Illness as Assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S)
Severity of illness as assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) -The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
Time frame: baseline, week 12 (LOCF)
Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Mania Score
The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7= Among the most extremely ill patients. A higher score is associated with greater illness severity
Time frame: baseline, week 12 (LOCF)
Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Depression Scale
The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and range from 1=normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with greater illness severity.
Time frame: baseline, week 12 (LOCF)
Change From Baseline to Week 12 (LOCF) in the SDS Total Score
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
Time frame: baseline, week 12 (LOCF)
| Milestone | Lurasidone |
|---|---|
| Started | 377 |
| Completed | 338 |
| Not completed | 39 |
| Withdrew: Adverse event | 9 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Administration | 1 |
Number of subjects with treatment emergent AEs, SAEs, and TEAEs leading to discontinuation
| participants | Lurasidone |
|---|---|
| at Least 1 TEAE potentially related to study drug | 155 |
| subjects with at least one TEAE potentially relate | 69 |
| at least 1 treatment emergent SAE | 14 |
| at least 1 treatment emergent SAE related to drug | 1 |
| at least 1 TEAE leading to discontinuation | 9 |
The QIDS-SR16 is a 16-item self-report measure of depressive symptomatology which uses a computerized assessment interface for administration. The scoring system for the QIDS-SR16 converts responses to 16 separate items into nine DSM-IV symptom criterion domains. The nine domains comprise: depressed mood (Item 5); concentration/decision making (Item 10); self outlook (Item 11); suicidal ideation (Item 12); decreased interest (Item 13); decreased energy (Item 14); sleep disturbance (initial, middle, and late insomnia or hypersomnia) (highest score of Items 1 to 4); appetite/weight disturbance (highest score of Items 6 to 9); and psychomotor disturbance (highest score of Items 15 and 16). The QIDS-SR16 total score is calculated as the sum of the 9 domain scores. The QIDS-SR16 total score ranges from 0 to 27 with a high score indicating more severe symptoms.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR16) Total Score | -1.0 ± 3.23 |
The PANSS-P is a subset of items in the PANSS, an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS-P subscale score is the sum of the 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the Positive and Negative Syndrome Scale Positive Subscale (PANSS P) Score | -0.2 ± 1.16 |
Movement disorders as assessed by Young Mania Rating Scale (YMRS) The YMRS is an 11-item instrument used to assess the severity of mania in subjects with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observation (accorded greater score). The YMRS total score is calculated as the sum of the 11 items. The YMRS total score ranges from 0 to 60. Higher scores are associated with greater severity of mania.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the YMRS Total Score -Mania as Assessed by Young Mania Rating Scale (YMRS) | -1.0 ± 5.17 |
Depression as assessed by Montgomery-Asberg Depression Rating Scale (MADRS) -The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity of depression.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the MADRS Total Score- Depression as Assessed by Montgomery-Asberg Depression Rating Scale (MADRS) | -1.9 ± 6.82 |
Severity of illness as assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) -The CGI-BP-S overall score is a single value, clinician-rated assessment of overall bipolar illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Overall Score- Severity of Illness as Assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) | -.31 ± 1.068 |
The CGI-BP-S mania score is a single value, clinician-rated assessment of mania illness severity and ranges from 1=Normal, not at all ill to 7= Among the most extremely ill patients. A higher score is associated with greater illness severity
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Mania Score | -0.13 ± 0.807 |
The CGI-BP-S depression score is a single value, clinician-rated assessment of depression illness severity and range from 1=normal, not at all ill to 7=Among the most extremely ill patients. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the CGI-BP-S Depression Scale | -0.27 ± 0.969 |
The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors in the patient's life are impaired by depressive symptoms. The SDS total score is calculated as the sum of the 3 items. The SDS total score ranges from 0 to 30. Higher scores are associated with greater severity of global functional impairments. If a subject has not worked/studied at all during the past week for reasons unrelated to the disorder, the SDS total score will be set to missing.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the SDS Total Score | -1.4 ± 5.98 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 14/377 (3.7%) | 51/377 (13.5%) |
| Event | Lurasidone |
|---|---|
| depressionPsychiatric disorders | 4/377 |
| maniaPsychiatric disorders | 2/377 |
| anaemia megaloblasticBlood and lymphatic system disorders | 1/377 |
| craniocerebral injuryInjury, poisoning and procedural complications | 1/377 |
| femur fractureInjury, poisoning and procedural complications | 1/377 |
| intentional overdoseInjury, poisoning and procedural complications | 1/377 |
| basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/377 |
| bipolar disorderPsychiatric disorders | 1/377 |
| emotional distressPsychiatric disorders | 1/377 |
| panic attackPsychiatric disorders | 1/377 |
| Event | Lurasidone |
|---|---|
| headacheNervous system disorders | 15/377 |
| nasopharyngitisInfections and infestations | 13/377 |
| akathisiaNervous system disorders | 12/377 |
| insomniaPsychiatric disorders | 11/377 |
| nauseaGastrointestinal disorders | 8/377 |
| Age, Categorical(Participants) | Lurasidone |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 359 |
| >=65 years | 17 |
| Age, Continuous(years) | Lurasidone |
|---|---|
| Mean | 45.5 ± 12.27 |
| Sex: Female, Male(Participants) | Lurasidone |
|---|---|
| Female | 206 |
| Male | 171 |
| Ethnicity (NIH/OMB)(Participants) | Lurasidone |
|---|---|
| Hispanic or Latino | 62 |
| Not Hispanic or Latino | 315 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Lurasidone |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 15 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 28 |
| White | 327 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
| Region of Enrollment(participants) | Lurasidone |
|---|---|
| Czech Republic | 40 |
| Russian Federation | 42 |
| Argentina | 30 |
| Hungary | 21 |
| United States | 95 |
| Japan | 13 |
| Poland | 37 |
| Slovakia | 5 |
| Bulgaria | 34 |
| France | 8 |
| Chile | 17 |
| Serbia | 35 |
The record gives a start of Jun 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →